Background: The current study evaluated the efficacy of an individualized, hand-held computer-delivered treatment (CDT) versus standard treatment (ST) for the maintenance of smoking abstinence following a quit attempt.
Introduction
Smoking is the most preventable cause of premature morbidity and mortality in the United States (1) and the health benefits of quitting are substantial. Unfortunately, of the 34% of adult smokers who make a serious quit attempt each year, only 7.5% are successful (2) . One promising approach to increasing cessation rates may be the use of computer-delivered treatment (CDT) provided via a small, mobile computer or smartphone. CDT might be particularly efficacious because it could be individualized on the basis of smoking preferences and empirical data, and would allow the provision of treatment in-the-moment when high-risk situations arose. The current study examined the efficacy of an individualized CDT program for smoking cessation used as an adjuvant to a standard treatment (ST). We hypothesized that CDT would increase abstinence rates through 1 year postquit relative to ST.
Method

Study design
This study was a 2 group randomized controlled trial of a palmtop computer-delivered, individualized smoking cessation intervention for adult smokers (N ¼ 303). Smokers were randomized into CDT (n ¼ 152) or ST (n ¼ 151).
Participants
Participants were recruited from Seattle, WA (n ¼ 139), and Houston, TX (n ¼ 164). Enrollment spanned 1999 to 2003. Data collection completed in 2004. Inclusion criteria were as follows: aged 18-70 years; !10 cigarettes per day for the past year; expired breath carbon monoxide level of !10 ppm; and the ability to speak/read/write in English. Exclusion criteria were as follows: regular use of tobacco products other than cigarettes; active substance abuse disorder; current psychiatric disorder; current use of bupropion; or contraindications for nicotine replacement therapy (NRT).
Procedure
Participants provided written informed consent, completed baseline measures, and were assigned a quit date. All were asked to complete assessments on a palmtop computer during the week before quitting. Assessments queried high-risk situations for smoking and efficacy and outcome expectancies for context-specific coping strategies. All participants received ST, which consisted of a self-help manual, information about how to access the Committed Quitters Program, and 6 weeks of the NRT patch. Participants randomly assigned to the CDT group also utilized individualized CDT through 1 month postquit.
CDT intervention consisted of 3 components: Treatment Information about smoking (e.g., risks of smoking, benefits of quitting) and specific tips on quitting (e.g., managing negative emotions, what to do if a lapse occurs); Motivational Messages to encourage quitting; and Managing My Urge, a list of situation-specific and affectively relevant coping strategies that could be accessed at the moment of an urge. Coping strategies were personalized to each person's preferences and experiences based on the pretreatment assessment and rating period. Participants were instructed to access the CDT program components to get assistance managing urges or whenever they needed additional information/guidance.
Measures
Sociodemographic and tobacco-related characteristics were measured at baseline and included self-reported race/ethnicity, age, gender, education, marital status, and the number of cigarettes smoked per day before quitting (smoking rate).
Smoking abstinence was assessed at week 1, and months 1, 6, and 12 after the target quit date. Abstinence was defined as a self-report of no smoking during the previous 7 days and an expired air carbon monoxide level of less than 10 ppm. Participants with missing data were classified as smokers per intent-to-treat procedures.
Data analyses
All analyses were conducted using Statistical Analysis Software (version 9.1). Preliminary analyses compared the ST and CDT groups on sociodemographic characteristics and smoking rate. Primary analyses examined the efficacy of CDT on abstinence over time using logistic random intercept models. Model 1 controlled for study site and time, and model 2 further adjusted for race/ ethnicity, age, gender, education, marital status, and smoking rate.
Results
Preliminary analyses
There were no significant differences between the CDT and ST groups on any of the sociodemographic characteristics or smoking rate (Table 1) .
Primary analyses
Abstinence rates for CDT versus ST at week 1, and months 1, 6, and 12 were as follows: 52.6% versus 55%, Table 1 . Participant characteristics by treatment group 41.4% versus 47%, 14.5% versus 14.6%, and 11.2% versus 13.9%, respectively. There were no significant differences in abstinence by treatment group in models 1 or 2 ( Table 2) .
Discussion
Recent reviews of electronic portable devices suggest the efficacy of these modalities in affecting behavior change across a variety of behavioral areas including smoking cessation (3, 4) . Contrary to expectations, CDT was not more efficacious for smoking cessation than ST in this trial. Several possible explanations must be considered. It is possible that the intervention delivery device, format, or content was not appealing to participants. It is important to note that hand-held computers were not common at the time and were unfamiliar to most. Exposure to the pretreatment assessment required to individualize treatment may have diminished group differences, as may have use of NRT. In addition, the intervention may not have been intensive enough. While we report null findings, CDTs that are integrated with more commonly used and carried electronic devices (e.g., smartphones), that offer greater treatment personalization or are used for longer duration, may be more effective.
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